1.45
Alector Inc stock is traded at $1.45, with a volume of 737.12K.
It is down -2.68% in the last 24 hours and up +2.11% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$1.49
Open:
$1.47
24h Volume:
737.12K
Relative Volume:
0.96
Market Cap:
$144.99M
Revenue:
$100.56M
Net Income/Loss:
$-119.05M
P/E Ratio:
-1.1789
EPS:
-1.23
Net Cash Flow:
$-231.16M
1W Performance:
-17.61%
1M Performance:
+2.11%
6M Performance:
-12.65%
1Y Performance:
-74.65%
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALEC
Alector Inc
|
1.45 | 148.99M | 100.56M | -119.05M | -231.16M | -1.23 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
Dec-16-24 | Downgrade | Stifel | Buy → Hold |
Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Dec-14-23 | Upgrade | Stifel | Hold → Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Sep-25-23 | Initiated | Goldman | Sell |
Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-07-22 | Initiated | Mizuho | Buy |
Apr-13-22 | Initiated | Goldman | Sell |
Mar-08-22 | Downgrade | Stifel | Buy → Hold |
Sep-27-21 | Initiated | William Blair | Outperform |
Jan-15-21 | Resumed | BofA Securities | Buy |
Jun-24-20 | Initiated | H.C. Wainwright | Buy |
Apr-28-20 | Initiated | Goldman | Buy |
Mar-06-20 | Initiated | Citigroup | Buy |
Feb-27-20 | Initiated | Barclays | Overweight |
Feb-19-20 | Initiated | Stifel | Buy |
Nov-21-19 | Initiated | BTIG Research | Buy |
Mar-04-19 | Initiated | Barclays | Overweight |
Mar-04-19 | Initiated | BofA/Merrill | Buy |
Mar-04-19 | Initiated | Morgan Stanley | Overweight |
Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
How to build a custom watchlist for Alector Inc.Sector Rotation Strategy for Smart Traders - Newser
Market reaction to Alector Inc.’s recent newsRSI and MACD Signal Summary with Trends - Newser
Identifying reversal signals in Alector Inc.Free AI Powered High Return Stock Calls - Newser
Why Alector Inc. stock attracts strong analyst attentionPortfolio Risk Distribution Analysis Tool - Newser
When is Alector Inc. stock expected to show significant growthExpert Picks Watchlist For Every Investor - jammulinksnews.com
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment - TipRanks
What is the risk reward ratio of investing in Alector Inc. stockFinancial News Review For Consistent Profits - jammulinksnews.com
Risk adjusted return profile for Alector Inc. analyzedReal Chart Based Opportunity Identification - Newser
How to recover losses in Alector Inc. stockShort-Term Stock Trend Forecast Guide - Newser
Is Alector Inc. stock entering bullish territoryRSI and MACD Signal Summary with Trends - Newser
Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation - Insider Monkey
Alector Inc. Company Revenue and Profit Trends: A Deep DiveHigh Conviction Screener with Trend Matching - Newser
What is the dividend policy of Alector Inc. stockPre Market Recommendation With Low Risk - jammulinksnews.com
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call | ALEC Stock News - GuruFocus
Alector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business Update - Quiver Quantitative
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call - GlobeNewswire
Is Alector Inc. a candidate for recovery playShort-Term Growth Watch with Signal Prediction - Newser
Will Alector Inc. continue its uptrendROI Focused Setup With Drawdown Analysis - Newser
Competitive Positioning of Alector Inc.: Is It Leading or LaggingNews Based Entry Opportunity Alerts Detected - metal.it
How Alector Inc. stock performs during market volatilityMinimal Risk Growth Investment Opportunity Analysis - Newser
What makes Alector Inc. stock price move sharplyFree Real Time Stock Movement Analysis - Newser
Is a relief rally coming for Alector Inc. holdersFree Pattern Detection for Entry Confirmation - Newser
Regression analysis insights on Alector Inc. performancePredictive Screener for Daily Trade Watch - Newser
Is Alector Inc. stock poised for growthIntraday Strategy with Real Time Monitoring - Newser
Can Alector Inc. rally from current levelsOversold Reversal Picks with Buy Zone - Newser
Detecting support and resistance levels for Alector Inc.Day Trading Setup and Momentum Analysis - Newser
Technical Charts Suggest Momentum Shift in Alector Inc.Breakout Momentum Picks With Protection Outlined - metal.it
Top Risks to Consider Before Buying Alector Inc. StockBuy List With Technical Entry Triggers - Newser
Is It Too Early to Call Recovery in Alector Inc.Oversold Bounce Stock Play Ideas Gain Attention - metal.it
Alector (NASDAQ:ALEC) Upgraded to Outperform at Mizuho - Defense World
RSI Crosses Above 30 for Alector Inc. — Reversal in SightAI Driven Buy Alert Trade Blueprint Released - beatles.ru
What catalysts could drive Alector Inc. stock higher in 2025Daily Trading Ideas For Fast Growth - jammulinksnews.com
How does Alector Inc. generate profit in a changing economyLow Risk Report For Consistent Profits - jammulinksnews.com
Alector's Strategic Upgrade and High-Risk/High-Reward Investment Potential: Leveraging Mizuho's Outlook for Neurodegenerative Disease Breakthroughs - AInvest
Alector upgraded at Mizuho on high risk/higher-reward - MSN
What institutional investors are buying Alector Inc. stockRapid growth trajectories - jammulinksnews.com
Is it the right time to buy Alector Inc. stockBuild wealth faster with expert stock selection - jammulinksnews.com
This Texas Instruments Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Should I buy Alector Inc. stock before earningsReal-Time Investment Signal Forecast with AI - Newser
Mizuho upgrades Alector stock to Outperform on FTD drug prospects By Investing.com - Investing.com India
Mizuho upgrades Alector stock to Outperform on FTD drug prospects - Investing.com
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alector Inc Stock (ALEC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
GRASSO MARC | Chief Financial Officer |
Jun 02 '25 |
Sale |
1.34 |
16,488 |
22,068 |
296,072 |
Kenkare-Mitra Sara | President and Head of R&D |
Jun 02 '25 |
Sale |
1.34 |
23,890 |
31,974 |
512,252 |
Rosenthal Arnon | Chief Executive Officer |
Jun 02 '25 |
Sale |
1.34 |
52,087 |
69,713 |
2,414,657 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):